A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
Saved in:
| Title: | A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar. |
|---|---|
| Authors: | Stringer F; Takeda Pharmaceutical Company, Osaka, Japan., DeJongh J, Scott G, Danhof M |
| Source: | Journal of clinical pharmacology [J Clin Pharmacol] 2014 Apr; Vol. 54 (4), pp. 453-61. Date of Electronic Publication: 2013 Nov 20. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1552-4604 |
|---|---|
| DOI: | 10.1002/jcph.227 |
